Wells Fargo
TVRD

Wells Fargo’s Tvardi Therapeutics TVRD Stock Holding History

Wells Fargo’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.21K Sell
2,266
-3,767
-62% -$14.8K ﹤0.01% 6030
2025
Q4 		$25.9K Buy
6,033
+2,479
+70% +$22.2K ﹤0.01% 5724
2025
Q3 		$138K Buy
3,554
+1,045
+42% +$29.8K ﹤0.01% 5139
2025
Q2 		$58.5K Buy
2,509
+2,493
+15,581% +$59K ﹤0.01% 5457
2025
Q1 		$243 Sell
16
-11
-41% -$166 ﹤0.01% 6317
2024
Q4 		$496 Sell
27
-3
-10% -$33 ﹤0.01% 6311
2024
Q3 		$334 Sell
30
-4
-12% -$47 ﹤0.01% 6196
2024
Q2 		$316 Sell
34
-506
-94% -$12.1K ﹤0.01% 6180
2024
Q1 		$17.7K Buy
540
+29
+6% +$752 ﹤0.01% 5612
2023
Q4 		$13.7K Sell
511
-343
-40% -$14.2K ﹤0.01% 5743
2023
Q3 		$51.6K Sell
854
-388
-31% -$36.4K ﹤0.01% 5163
2023
Q2 		$127K Buy
1,242
+134
+12% +$18.5K ﹤0.01% 4886
2023
Q1 		$196K Buy
1,108
+137
+14% +$45.9K ﹤0.01% 4445
2022
Q4 		$376K Sell
971
-886
-48% -$336K ﹤0.01% 3817
2022
Q3 		$626K Sell
1,857
-114
-6% -$41.3K ﹤0.01% 3560
2022
Q2 		$647K Sell
1,971
-1,132
-36% -$397K ﹤0.01% 3578
2022
Q1 		$1.36M Sell
3,103
-586
-16% -$241K ﹤0.01% 3632
2021
Q4 		$1.62M Sell
3,689
-1,515
-29% -$761K ﹤0.01% 3702
2021
Q3 		$2.89M Sell
5,204
-1,014
-16% -$509K ﹤0.01% 3357
2021
Q2 		$3.19M Buy
6,218
+2,174
+54% +$1.38M ﹤0.01% 3269
2021
Q1 		$3.16M Buy
4,044
+525
+15% +$359K ﹤0.01% 3284
2020
Q4 		$1.92M Buy
3,519
+522
+17% +$274K ﹤0.01% 3530
2020
Q3 		$1.37M Sell
2,997
-314
-9% -$182K ﹤0.01% 3619
2020
Q2 		$2.04M Buy
3,311
+406
+14% +$224K ﹤0.01% 3249
2020
Q1 		$1.38M Buy
2,905
+75
+3% +$40.8K ﹤0.01% 3308
2019
Q4 		$1.64M Sell
2,830
-1,190
-30% -$835K ﹤0.01% 3501
2019
Q3 		$2.65M Sell
4,020
-379
-9% -$315K ﹤0.01% 3095
2019
Q2 		$3.4M Buy
4,399
+1,365
+45% +$959K ﹤0.01% 2897
2019
Q1 		$2.14M Sell
3,034
-59
-2% -$35.3K ﹤0.01% 3305
2018
Q4 		$1.45M Sell
3,093
-20
-0.6% -$12.9K ﹤0.01% 3547
2018
Q3 		$2.68M Buy
3,113
+642
+26% +$464K ﹤0.01% 3158
2018
Q2 		$1.7M Buy
2,471
+118
+5% +$60K ﹤0.01% 3586
2018
Q1 		$1.05M Buy
2,353
+1,796
+322% +$871K ﹤0.01% 3879
2017
Q4 		$246K Sell
557
-224
-29% -$102K ﹤0.01% 4857
2017
Q3 		$385K Sell
781
-56
-7% -$28K ﹤0.01% 4505
2017
Q2 		$465K Sell
837
-15
-2% -$9.52K ﹤0.01% 4267
2017
Q1 		$563K Buy
852
+187
+28% +$99.9K ﹤0.01% 4164
2016
Q4 		$223K Buy
665
+331
+99% +$106K ﹤0.01% 4710
2016
Q3 		$100K Buy
334
+187
+127% +$40.5K ﹤0.01% 4915
2016
Q2 		$26K Sell
147
-188
-56% -$40.9K ﹤0.01% 5428
2016
Q1 		$76K Buy
335
+38
+13% +$11.3K ﹤0.01% 5029
2015
Q4 		$180K Buy
297
+114
+62% +$62.6K ﹤0.01% 4527
2015
Q3 		$94K Sell
183
-77
-30% -$51.5K ﹤0.01% 4929
2015
Q2 		$114K Buy
260
+252
+3,150% +$97.4K ﹤0.01% 4983
2015
Q1 		$3K Buy
8
+1
+14% +$378 ﹤0.01% 5924
2014
Q4 		$2K Hold
7
– – ﹤0.01% 6029
2014
Q3 		$2K Sell
7
-5
-42% -$2.05K ﹤0.01% 6008
2014
Q2 		$8K Sell
12
-132
-92% -$71.1K ﹤0.01% 5698
2014
Q1 		$97K Buy
+144
New +$85.2K ﹤0.01% 4668

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Wells Fargo's TVRD Position: Q1 2026 in Review

Wells Fargo reduced its Tvardi Therapeutics (TVRD) stake by 62% in Q1 2026, selling an estimated $14.8K and leaving 2,266 shares worth $7.21K. The position accounts for ﹤0.01% of the portfolio, ranked #6030.

Wells Fargo first reported a position in TVRD in Q1 2014 and has held it in 49 quarters since. The position peaked at $3.4M in Q2 2019. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Wells Fargo held 2,266 shares of Tvardi Therapeutics worth $7.21K as of Q1 2026.
  • Wells Fargo sold 3,767 Tvardi Therapeutics shares in Q1 2026, an estimated $14.8K.
  • Tvardi Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6030 holding.
  • Wells Fargo first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Wells Fargo's Tvardi Therapeutics position peaked at $3.4M in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.